Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)-Reference-Cited by-同舟云学术

Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)

Published:2010-12-06 Issue:1 Volume:52 Page:34-41
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Venner Christopher P.,Connors Joseph M.,Sutherland Heather J.,Shepherd John D.,Hamata Linda,Mourad Yasser Abou,Barnett Michael J.,Broady Raewyn,Forrest Donna L.,Hogge Donna E.,Nantel Stephen H.,Narayanan Sujaatha,Nevill Thomas J.,Nitta Janet,Power Maryse M.,Toze Cynthia L.,Smith Clayton A.,Song Kevin W.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2010.531409

Reference19 articles.

1. Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

2. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

3. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

4. Improved survival in multiple myeloma and the impact of novel therapies

5. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of kidney transplant recipients with ESKD due to plasma cell dyscrasia: A case series;Clinical Transplantation;2021-11-30

2. Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients;Hematological Oncology;2021-08-02

3. Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN ‐003/ MYX .1 single arm phase II trial;American Journal of Hematology;2021-04-12

4. Approaching the first relapse after autologous transplant in multiple myeloma;ADVANCES IN CELL AND GENE THERAPY;2020-07-20

5. Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma;Clinical Lymphoma Myeloma and Leukemia;2020-07